Haemonetics (NYSE: HAE) announced today that it acquired percutaneous vessel closure device maker Vivasure Medical.

The purchase is expected to expand Haemonetics’ impact in fast-growing markets for structural heart and endovascular procedures.

Haemonetics will shell out up to 185 million euros ($216 million) to acquire Vivasure Medical, a Galway, Ireland-based medtech that makes arterial closure devices.

Orchestra BioMed (Nasdaq:OBIO) expects to receive up to $21 million in cash as a result of Haemonetics' recent.

BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a ...

The ELITE arterial study demonstrated ease of use for Vivasure's PerQseal Elite with no need for pre-close.

Haemonetics' acquisition of Vivasure adds PerQseal Elite, advancing large-bore closure solutions for TAVR and EVAR markets.

Vivasure Medical, a medtech based in Galway’s Parkmore West Business Park, has announced it is to be acquired by Haemonetics Corporation, a medical device company located in Boston, Massachusetts. The ...

Haemonetics (HAE) announced that it has entered into a definitive agreement to sell its whole blood assets to GVS, a manufacturer of filter solutions for applications in the healthcare and life ...

We recently published a list of 10 Pro-Life Companies to Invest In Now. In this article, we are going to take a look at where Haemonetics Corporation (NYSE:HAE) stands against other top pro-life ...

Haemonetics (HAE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham reiterated a Buy rating on the stock and has a ...